A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: COVID-19

In brief

This is a dose-finding, inferentially seamless Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314 in Ambulatory Patients with COVID-19.

Key facts

Study ID
NCT05162365
Run by
Innovent Biologics (Suzhou) Co. Ltd.
People needed
248
Starts
2022-01-06
Expected to finish
2022-11-18
Last updated by the study team
2023-12-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.